Jonathan Kolber appointed Chairman of Panaxia Pharmaceutical

March 26, 2019 | Market Screener

Panaxia Israel Pharmaceutical Industries, which manufactures medical cannabis treatments, announced today Jonathan Kolber’s appointment as Chairman of the merged company – Panaxia Israel-Herodium Investments. The appointment will take effect on May 1, 2019, subject to approval by Herodium board of directors and compensation committee, and to completing the merger between Panaxia and Herodium Investments.

Jonathan Kolber is partner and senior consultant in the private equity fund Viola Growth, which specialize in growing companies and constitutes part of the Viola Investment group. Kolber is a private equity veteran with over 30 years of experience in launching international investments, raising capital, achieving exits and actively running public companies. He’s served as Chairman, CEO and Director in over 60 public and private companies in Israel and Canada.

Between 1986-1997, he was Co-Founder and CEO of Claridge Israel, which grew from $50 to $700 million through a series of highly successful exits, including Teva Pharmaceuticals, ECI Telecom (acting as chairman), and Optrotec – all of which are listed on NASDAQ.

Between 1998-2006, he served as CEO of Koor Industries, where he steered and led a successful exit to IDB. Furthermore, Jonathan has served on the board of directors of many companies traded on the Israeli Stock Exchange, including: Itamar Medical, Makhteshim, Tadiran, Aeronautics, Knafaim, Gaon Holdings, and more.

Read More On:  Market Screener Website

Share on linkedin
Share on facebook
Share on twitter